EBS Emergent BioSolutions Inc.

CIK 0001367644 43 ready 8-Ks latest April 30, 2026, 7:59 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 43

Latest filing April 30, 2026, 7:59 PM ET

Top materiality 0.90

Event mix other_material ×15 · earnings ×9 · debt ×5

Sentiment 25 pos · 3 neg · 15 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for EBS

Highest-materiality recent filing

Emergent BioSolutions Q3 2024 revenue $293.8M (+9% YoY), net income $114.8M, raises FY2024 guidance

November 6, 2024, 6:59 PM ET earnings materiality 0.90 positive item 2.02 item 7.01 item 9.01

Q3 2024 total revenues $293.8M, up 9% year-over-year; net income $114.8M vs loss of $263.4M in Q3 2023.
Adjusted EBITDA surged 432% to $105.3M; company raises FY2024 revenue guidance to $1.065B-$1.125B.

Read filing →

April 30, 2026, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×3

Q1 revenue $156.1M (-30% YoY); net income slumps 90%; guidance raised on adjusted EBITDA

Revenue $156.1M vs $222.2M in Q1 2025; net income $6.8M ($0.07 EPS) vs $68.0M ($1.19 EPS).
April 17, 2026, 7:59 PM ET debt materiality 0.60 positive item 1.01 item 1.02 item 3.02 item 2.03 item 7.01 item 9.01 ◈ Material Agreements ×2◈ Debt Financings

Emergent BioSolutions closes $150M Term Loan with OrbiMed, extends maturities, cuts interest expense 200 bps

New $150M Term Loan with OrbiMed matures April 2031, replaces prior $150M OHA facility; ABL reduced to $50M.
February 26, 2026, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 9.01

EBS Q4 net loss $1.04/sh, FY2025 net income $0.93/sh; FY2026 rev guidance $720-760M

Full year 2025 total revenues $742.9M, down 29% from $1,043.6M in 2024.
January 12, 2026, 6:59 PM ET debt materiality 0.75 positive item 7.01 item 9.01

Emergent BioSolutions voluntarily prepays $100M of term loan; total debt reduced by $275M since 2023

Voluntary prepayment of $100M on term loan using cash on hand in late December 2025.
December 12, 2025, 6:59 PM ET regulatory materiality 0.65 positive item 7.01 item 9.01

Emergent BioSolutions receives FDA approval for raxibacumab manufacturing at Winnipeg site

FDA approved sBLA for Winnipeg as drug product manufacturing and testing site for raxibacumab.
October 29, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Emergent Q3 revenue $231.1M beats guidance; raises FY2025 revenue & EBITDA view

Total revenue $231.1M (above Q3 guidance high by $21M); net income $51.2M ($0.91 EPS).
September 11, 2025, 7:59 PM ET other material materiality 0.65 positive item 1.01 item 7.01 item 9.01

Emergent gets $56M ACAM2000 contract modification; 2025 sales projected >$120M

Contract Modification No. 14 valued at $56M; deliveries to U.S. government by Dec 31, 2025.
September 5, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Emergent BioSolutions awarded $30M BARDA contract modification for CYFENDUS anthrax vaccine

Modification No. 20 valued at $30M for additional doses of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted).
August 6, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Emergent BioSolutions Q2 revenue $140.9M, beats guidance; raises FY profitability outlook

Q2 revenue $140.9M (above Q2 guidance by $21M); net loss improved to $12.0M from $283.1M loss a year ago.
June 24, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Emergent BioSolutions secures $62.4M contract modification from ASPR for botulism antitoxin BAT

Modification and option exercise valued at $62.4 million under existing 10-year ASPR contract (75A50119C00075).
May 23, 2025, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Court grants preliminary approval of $15M derivative suit settlement; final hearing Aug 6

Settlement covers five derivative actions alleging breach of fiduciary duty over Bayview vaccine manufacturing failures.
May 7, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Emergent BioSolutions Q1 net income surges 656% to $68M; revenue down 26% to $222.2M

Total revenues $222.2M, down 26% YoY; driven by 62% drop in NARCAN sales to $45.3M.
March 24, 2025, 7:59 PM ET M&A materiality 0.60 positive item 7.01 item 8.01 item 9.01

Emergent closes sale of Baltimore-Bayview facility to Syngene for ~$36.5M

Sale closed on March 19, 2025; Emergent received ~$36.5M at closing, subject to post-closing adjustments.
March 10, 2025, 7:59 PM ET M&A materiality 0.65 positive item 7.01 item 8.01 item 9.01

Emergent BioSolutions sells Baltimore-Bayview manufacturing site to Syngene for $36.5M

Sale of Bayview drug substance manufacturing facility to Syngene Intl for ~$36.5M; closing expected Q1 2025.
March 3, 2025, 6:59 PM ET earnings materiality 0.80 neutral item 2.02 item 7.01 item 9.01

Emergent BioSolutions Q4 loss narrows 37% to $31.3M; FY24 revenue $1.04B; guides FY25 EBITDA $150-200M

Q4 2024 total revenue $194.7M, down 30% YoY; net loss $31.3M vs. $49.5M loss in Q4 2023.
January 14, 2025, 6:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Emergent gains exclusive U.S./Canada commercial rights to Hikma's KLOXXADO 8 mg naloxone spray

Six-year agreement gives Emergent exclusive rights to market and distribute KLOXXADO (naloxone HCl) 8 mg nasal spray in U.S. and Canada.
January 8, 2025, 6:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

Emergent receives $50M BARDA CYFENDUS option and $20M DoD BioThrax option

BARDA awarded $50M option for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted); deliveries through April 2025.
November 6, 2024, 6:59 PM ET earnings materiality 0.90 positive item 2.02 item 7.01 item 9.01

Emergent BioSolutions Q3 2024 revenue $293.8M (+9% YoY), net income $114.8M, raises FY2024 guidance

Q3 2024 total revenues $293.8M, up 9% year-over-year; net income $114.8M vs loss of $263.4M in Q3 2023.
October 2, 2024, 7:59 PM ET debt materiality 0.60 positive item 1.01 item 2.02 item 2.03 item 7.01 item 9.01

Emergent BioSolutions closes $100M ABL credit facility, reports $150M cash balance

New asset-based revolving loan facility of up to $100M, maturing September 2029.
September 3, 2024, 7:59 PM ET debt materiality 0.80 positive item 1.01 item 1.02 item 2.03 item 3.02 item 7.01 item 8.01 item 9.01

Emergent BioSolutions closes $250M term loan with Oak Hill Advisors; extends maturity to 2029

$250M term loan drawn in full, matures August 2029; used to repay existing senior term loan due May 2025 and terminate revolver.
August 30, 2024, 7:59 PM ET regulatory materiality 0.75 positive item 7.01 item 8.01 item 9.01

Emergent BioSolutions gets FDA approval for ACAM2000 mpox indication

FDA approved sBLA for ACAM2000 to prevent mpox in high-risk individuals based on animal study safety/efficacy data.
August 6, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 7.01 item 9.01

Emergent BioSolutions Q2 revenue $254.7M, net loss $283.1M; updates FY2024 guidance

Q2 revenue $254.7M (above guidance); net loss $283.1M ($5.38/diluted), adjusted EBITDA -$10.1M.
July 31, 2024, 7:59 PM ET M&A materiality 0.75 positive item 1.01 item 7.01 item 9.01

Emergent BioSolutions sells RSDL decontamination kit to SERB for $75M

Cash purchase price of $75M at closing; additional $5M milestone payment for component sourcing.
July 8, 2024, 7:59 PM ET litigation materiality 0.75 positive item 8.01

Emergent settles Janssen COVID vaccine manufacturing dispute; receives $50M

Janssen will pay Emergent $50M by July 31, 2024 under settlement agreement.
July 2, 2024, 7:59 PM ET other material materiality 0.75 positive item 1.01 item 7.01 item 8.01 item 9.01

Emergent secures $250M+ in U.S. gov't contracts for smallpox, anthrax, botulism meds

Modification 12 for ACAM2000 smallpox vaccine valued at $99.9M; delivery by Sept 30, 2024.
June 20, 2024, 7:59 PM ET M&A materiality 0.65 positive item 7.01 item 8.01 item 9.01

Emergent BioSolutions sells Baltimore-Camden facility to Bora for $30M

Sale of drug product facility to Bora Pharmaceuticals affiliate for total value of ~$30 million.
May 29, 2024, 7:59 PM ET other material materiality 0.65 neutral item 5.02 item 5.07 item 7.01 item 9.01

Emergent BioSolutions approves 2.1M share increase to stock plan; reports NARCAN OTC launch, DoD contracts

Stockholders approved 2.1M share increase to stock incentive plan; full-value awards now count one-for-one.
May 1, 2024, 7:59 PM ET other material materiality 0.75 negative item 2.05 item 7.01 item 9.01

Emergent BioSolutions to cut ~300 jobs, close two facilities, targeting $80M annual savings

Reduces workforce by ~300 employees and eliminates ~85 vacant positions across all areas.
May 1, 2024, 7:59 PM ET earnings materiality 0.75 positive item 1.01 item 2.02 item 7.01 item 9.01

Emergent Q1 rev $300M, net income $9M; raises FY2024 adj EBITDA guidance to $125-175M

Q1 2024 total revenues $300.4M (up 83% YoY), net income $9.0M vs loss of $186.2M last year.
April 30, 2024, 7:59 PM ET debt materiality 0.75 negative item 1.01 item 2.03 item 9.01 ◈ Debt Financings◈ Material Agreements

Emergent BioSolutions amends credit facility; revolver cut to $270M, interest margins raised

Revolving commitments reduce to $270M through July 30, then $225M, and $200M after Oct 31, 2024.
April 26, 2024, 7:59 PM ET other material materiality 0.60 neutral item 5.02 item 9.01

Emergent BioSolutions awards $1.45M in additional retention bonuses to four top executives

CFO Richard Lindahl receives $399,753; GC Jennifer Fox $380,250; EVP Quality Coleen Glessner $373,761; SVP Products Paul Williams $292,501.

Executive changes

Departed

Jennifer Fox

Executive Vice President External Affairs, General Counsel and Corporate Secretary

EBS · Emergent BioSolutions Inc.

Effective: 2024-08-16
Filed: July 30, 2024, 7:59 PM ET

Emergent BioSolutions, Inc. (the “Company”) announced that Jennifer Fox is resigning as Executive Vice President External Affairs, General Counsel and Corporate Secretary of the Company to pursue an opportunity outside of the Company and will continue in her current role until August 16, 2024.

Earnings & guidance

2026-Q1 EPS reported $0.07 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

25 positive 3 negative 15 neutral

source · EBS on sec.gov